Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at email@example.com and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
Long-running speculation about the future of Novartis' struggling vaccine business now appears to be nearing an end. One way or another, Novartis CEO Joe Jimenez expects the future of the unit to be settled in the coming months.
Since an FDA advisory panel unanimously recommended GlaxoSmithKline's H5N1 vaccine one year ago, links between the vaccine's adjuvant and narcolepsy have strengthened, and the FDA subsequently delayed approval. Now, though, GSK has received its long-sought FDA approval.
The trial found two doses of the adjuvanted cell culture vaccine immunologically protected 85% of participants.
The European Union began looking for a solution to vaccine instability earlier this year, and is now nearing the end of its search. A decision is expected next month, after which the EU will commit $3 million to support development of the vaccine temperature stability project.
China is a big, climatologically-diverse country, with the weather changing significantly between the temperate zones in the north and the subtropical regions further south. This affects when flu seasons occur, and consequently when health authorities should run vaccination campaigns.
When the World Health Organization released its first malaria vaccine technology roadmap in 2006, it put the development of a partly effective vaccine by 2015 at the top of its list of priorities. With GlaxoSmithKline nearing that goal, WHO has revised its plan with new targets for 2030.
While anthrax, smallpox and other "category A" bioterrorism threats dominate the collective public consciousness, a larger pool of lower-priority agents are also a danger. Q fever falls into this second tier, but the U.S. government is still sufficiently concerned to gather researchers to talk vaccine development.
As a meningitis outbreak has slowly spread across Princeton University over the past 8 months, the case for vaccinating students has grown stronger. The only hitch is that the vaccine, Novartis' Bexsero, has yet to win approval in the U.S. Now, though, health authorities are willing to work around this obstacle.
U.K. adds schools to flu data-gathering project
U.K. health authorities have run similar surveys over the past four years, but this is the first time it will capture data from schools.
The reemergence of H7N9 in China during the past month has reinforced the need for a vaccine. Candidates from Chinese and Taiwanese manufacturers have grabbed the headlines recently, but now a U.S. player, Novavax, has joined the race with positive Phase I data.